Grifols, ES0171996087

CaixaBank sets EUR 19.00 target for Grifols stock

Published on 10/23/2026 at 09:24 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Profit rose 28.70 percent to EUR 227 million in the first half. Grifols stock trades at EUR 10.08 on October 23, 2026, versus the EUR 19.00 target.

Analyst views and results

CaixaBank kept a EUR 19.00 target for Grifols on October 21, 2026.
First-half revenue reached EUR 3.574 billion, up 2.60 percent at constant currency.
Grifols stock trades at EUR 10.08 at 9:14 a.m. CEST at Lang & Schwarz on October 23, 2026.
MarketBeat estimates third-quarter results for November 10, 2026.

Aquarellbild von Barcelona mit Hafen, Bergen und mediterranem Licht — Aquarellmalerei zeigt die Küstenstadt Barcelona als Sitz von Grifols S.A. ES0171996087 in weichen, warmen Farbtönen, Illustration mit AI erstellt.

Grifols (ES0171996087) was trading at EUR 10.08 at Lang & Schwarz on October 23, 2026 at 9:14 a.m. CEST. On October 21, 2026, XTB reported opposing views from CaixaBank and Oddo BHF, including a EUR 19.00 target from CaixaBank and a EUR 9.00 target from Oddo BHF.

Two targets frame the debate

The split leaves a wide valuation gap around the stock. CaixaBank's EUR 19.00 target is 90.48 percent above the Lang & Schwarz price, while Oddo BHF's EUR 9.00 target is 10.71 percent below it, based on the October 21, 2026 report.

The debate reflects both recovery potential and execution risk. XTB said Grifols had begun reopening two Canadian plasma centers in Winnipeg and Edmonton after an August interruption, while the Taylor Avenue license remained suspended and 16 other Canadian locations operated under stricter conditions.

What does the margin target require?

Grifols entered the second half with improving operating figures. The company reported first-half revenue of EUR 3.6 billion, up 2.6 percent at constant currency, and net profit of EUR 227 million, up 28.7 percent, in its investor update dated July 28, 2026.

Its first-half adjusted EBITDA reached EUR 854 million, up 2.4 percent at constant currency, with an adjusted EBITDA margin of 23.9 percent. In the earnings-call transcript, Yahoo Finance carried management's full-year 2026 adjusted EBITDA margin target of at least 25.00 percent.

Results date sets the next test

The stock's next scheduled evidence point is third-quarter reporting. MarketBeat estimates the results announcement for November 10, 2026 and lists a conference call for November 3, 2026. For investors, the key issue is whether Biopharma growth and cost actions can lift margins while plasma operations in Canada normalize.

Trading stays tied to execution

The first-half figures provide a stronger operating base, but the opposing targets show how much the valuation depends on debt reduction, plasma availability and margin delivery.

Grifols was trading at EUR 10.08 at Lang & Schwarz on October 23, 2026 at 9:14 a.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Grifols stock.